S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
All the trading advice you’ve ever received boils down to this (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
All the trading advice you’ve ever received boils down to this (Ad)
2 energy drink makers to wake up your portfolio
Snowflake’s bullish tailwind is turning into a gale-force wind

Karuna Therapeutics (KRTX) Stock Forecast & Price Target

$197.57
+1.04 (+0.53%)
(As of 12/4/2023 ET)
Compare
Today's Range
$192.08
$199.37
50-Day Range
$161.01
$197.57
52-Week Range
$158.38
$245.00
Volume
213,199 shs
Average Volume
328,990 shs
Market Capitalization
$7.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$259.38

Karuna Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 12 Analyst Ratings

Analysts' Consensus Price Target

$259.38
31.29% Upside
High Forecast$318.00
Average Forecast$259.38
Low Forecast$209.00
TypeCurrent Forecast
12/5/22 to 12/5/23
1 Month Ago
11/5/22 to 11/5/23
3 Months Ago
9/6/22 to 9/6/23
1 Year Ago
12/5/21 to 12/5/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
10 Buy rating(s)
14 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$259.38$259.77$263.50$259.47
Predicted Upside31.29% Upside40.65% Upside34.79% Upside25.21% Upside
Get Karuna Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for KRTX and its competitors with MarketBeat's FREE daily newsletter.


KRTX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

KRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Karuna Therapeutics Stock vs. The Competition

TypeKaruna TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.83
2.67
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside31.29% Upside651.36% Upside2,853.10% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/20/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$300.00+66.92%
11/17/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform ➝ Market Outperform$318.00+77.27%
11/17/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$253.00+44.60%
11/3/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$235.00 ➝ $225.00+21.85%
11/3/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$332.00 ➝ $296.00+61.87%
9/8/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$304.00 ➝ $259.00+40.12%
8/22/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Duncan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$214.00+22.26%
8/22/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$225.00+28.65%
8/4/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$280.00+51.89%
8/4/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$274.00 ➝ $258.00+38.12%
6/5/202358.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
6/5/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$260.00 ➝ $250.00+7.00%
1/27/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$209.00+6.59%
1/5/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$285.00+43.61%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:23 AM ET.












KRTX Price Target - Frequently Asked Questions

What is Karuna Therapeutics's consensus rating and price target?

According to the issued ratings of 12 analysts in the last year, the consensus rating for Karuna Therapeutics stock is Moderate Buy based on the current 2 hold ratings and 10 buy ratings for KRTX. The average twelve-month price prediction for Karuna Therapeutics is $259.38 with a high price target of $318.00 and a low price target of $209.00. Learn more on KRTX's analyst rating history.

Do Wall Street analysts like Karuna Therapeutics more than its competitors?

Analysts like Karuna Therapeutics more than other Medical companies. The consensus rating score for Karuna Therapeutics is 2.83 while the average consensus rating score for medical companies is 2.67. Learn more on how KRTX compares to other companies.

Does Karuna Therapeutics's stock price have much upside?

According to analysts, Karuna Therapeutics's stock has a predicted upside of 39.82% based on their 12-month stock forecasts.

What analysts cover Karuna Therapeutics?

Karuna Therapeutics has been rated by Bank of America, HC Wainwright, JMP Securities, Royal Bank of Canada, The Goldman Sachs Group, and Wedbush in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:KRTX) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -